ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2011
The cell cycle.
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Arrest of nuclear division in Plasmodium through blockage of erythrocyte surface exposed ribosomal protein P2.PLoS pathogens · 2012Trial
- A guide to the apicomplexan cell cycle: endodyogeny and schizogony.Trends in parasitology · 2025Review
- Targeting CDK7/12/13 functional synergism reverses myofibroblast activation and ameliorates lung fibrosis.iScience · 2025Article
- Deep learning-driven imaging of cell division and cell growth across an entire eukaryotic life cycle.Molecular biology of the cell · 2025Article
- Article
- Selectively advantageous instability in biotic and pre-biotic systems and implications for evolution and aging.Frontiers in aging · 2024Review
- Article
- Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.Journal of cancer research and clinical oncology · 2023Review
- Cell cycle regulators and bone: development and regeneration.Cell & bioscience · 2023Review
- CDK inhibitor Palbociclib targets STING to alleviate autoinflammation.EMBO reports · 2022Article
- Article
- The role of APC/C in cell cycle dynamics, growth and development in cereal crops.Frontiers in plant science · 2022Review
- Article
- Modeling Progression of Single Cell Populations Through the Cell Cycle as a Sequence of Switches.Frontiers in molecular biosciences · 2021Article
- Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes.Molecular and clinical oncology · 2020Article
- Polyploid Giant Cancer Cells, a Hallmark of Oncoviruses and a New Therapeutic Challenge.Frontiers in oncology · 2020Review
- Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.Cancers · 2019Article
- MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate.Acta pharmaceutica Sinica. B · 2019Article
- CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.Current oncology reports · 2019Review
- Biological interactions of biocompatible and water-dispersed MoSScientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.